Platinum Level | Gold Level | Silver Level | Bronze Level |
• Neurospine expresses sincere gratitude to our proud corporate supporters.
• Neurospine and Corporate sponsors should follow regulation of Fair Trade Act of Korea.
• Editorial and review activities of Neurospine are strictly independent from corporate supporters.
• Neurospine staff would be happy to discuss with potential corporate supporters in additional partnership prospects.
CG Bio is a total healthcare provider with a goal of enhancing the quality of life by offering range of innovative solutions for the spectrum of spinal disorders. Through extensive research activity, CG Bio is a leading comprehensive portfolio of allograft and synthetic bone grafts, spinal implants, and Growth Factor rh-BMP2. Cell & Growth Factor Biotechnology.
Powered by our portfolio of Advanced Surgery products:
The haemostats trusted to stop the bleeding.
The sealants clinicians count on to close the wounds.
The tissue and bone repair solutions surgeons rely on to promote healing.
Because they have confidence that these products will work. With Baxter’s advanced surgery solutions, it’s the details that make a big difference. Driving clinician confidence. Reducing the time patients spend in the OR. Creating efficiencies. Impacting clinical outcomes – and real lives. Across specialties. Throughout health systems. Around the globe. Merging art and science, Together with our clinical partners, we embody hope and empower healing.
Baxter. Advanced Surgery Advancing the art of healing.
Since its establishment in 1997, Cellumed Co.,Ltd is a bio company that manufactures and supplies medical devices, biologics, and cosmeceuticals under the corporate philosophy of respecting human beings.
We succeeded in developing and mass-producing animal(CHO cell)-derived bone formation protein rhBMP2 for the first time in Asia and the second in the world. Our own Rafugen ™ DBM Gel that Cellumed developed has obtained FDA approval in 2018, thus our biotechnology is also well acknowledged overseas. In addition to distributing allografts, it is leading tissue bank in Korea that has the technology to directly process and sterilize human tissues, and is managed by the Ministry of Food and Drug Safety (MFDS) every year to handle safe human tissues.
In order to contribute to human health, Cellumed spares no investments in research and development, such as medical devices and biotechnology, and strives to provide the best products and services.
In 1958, Daewon Pharm was established on the basis of founding idea: “the realization of human health.” Although we went through chronological changes, it has been our unchanging role and mission to protect the public health as a company specialized in therapeutic agents.
Daewon Pharm is capable company that has developed new drugs using excellent technological basis and manufacturing facility.
We are devoting ourselves to develop numerous new products to improve the quality of life, and trying our best to become the representative pharmaceutical company of the Republic of Korea.
Comprehensive Solution Rapidly Changing Spine Industry
In this rapidly changing healthcare industry, every stakeholder faces their unique challenges. Surgeons, hospitals, distributors, and even patients, all need to rethink where to hang their hats. Based on spine industry expertise that GS Medical has gained since its founding in 2011, we have become one of few companies that understand current market challenges and provide optimized solutions for every stakeholder. With our New Spine Standard, you’ll find the way to succeed in this changing healthcare industry.
inno.N has technology-focused business competitiveness in the fields of ETC Drugs, APIs, and Health & Beauty Care.
In 2019, inno.N launched the new medicine for gastroesophageal reflux disease, "K-CAB Tab.," was released as the 30th new drug in Korea. Furthermore, inno.N unrivaled in the basic IV fluids and anti-hangover drink markets.
It has more than 20 new drug and biopharmaceutical pipelines centered on digestion, oncology, liver, Auto immune, and infection, and recently established a future growth engine by entering the cell gene therapy business.
With the 'Heal the World For Better Life' mission, inno.N will develop innovative new drugs and become a global pharmaceutical company that customers can trust.
L&K BIOMED is a publicly listed company that has strived to distribute superior products around the world for the past 10 years. Through our international offices and subsidiaries, we develop products based on customer feedback and market trends in order to enhance the quality for patients and surgeons. We are currently developing innovative technology which can be applied to a wide range of spine diseases.
L&K BIOMED aims to improve product quality and to develop new products that covers multiple surgical approaches with streamlined, user-friendly instrument and implant systems. Our competitive technology provides enhanced quality of life and leads to new trends in the medical industry.
Medtronic, headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 84,000 people worldwide, serving physicians, hospitals and patients in more than 160 countries. The company is committed to transforming healthcare especially in the areas of Therapy Innovation; providing a spectrum of offerings aimed at improving both economic and patient outcomes, Globalization; Adapting our thinking to address healthcare access challenges in both developed and developing countries, and Economic Value; Thinking more holistically about the care continuum, and how we can lead the creation of value-based healthcare solutions.
Medtronic’s business consists of four groups; Cardiac & Vascular Group, Diabetes Group, Minimally Invasive Therapies Group and Restorative Therapies Group. The Cardiac & Vascular Group products include Implantable devices like pacemakers, ICDs to correct heart rhythm issues, drug-coated balloons to open blocked arteries and so on. Diabetes Group focuses on computerized insulin pumps, injection ports and mobile monitoring. Minimally Invasive Therapies Group offers solutions that enable earlier diagnosis, better treatment, faster complication-free recovery, and enhanced patient outcomes through less-invasive treatments. Restorative Therapies Group provides Implantable deep-brain stimulation systems, revascularization devices and other pain therapies.
Established in 1945, Daewoong Pharmaceutical Co., Ltd. has the largest prescription drug sales in Korea and envisions itself to become a top 50 global healthcare company by 2020.
In addition to its product portfolio, which includes 15 blockbuster products, Daewoong has built strong core competency for new drug development and has cultivated a cooperative culture for collaboration with global partners.
In the future, Daewoong will expand its global business with its foreign branches and global partners and become a global healthcare group which contributes to improving the quality of life for people worldwide.
Since its establishment in 2004, GENOSS strictly fulfills and complies with the international quality regulations, including KGMP, ISO 13485 and ISO 9001. Furthermore, the CE mark on each product confirms its conformity with all of the legal requirements. GEONSS always concentrates on our customers and patients with the very high levels of innovation and technical expertise, providing a wide range of products categorized as 3d cage, peek cage, and Bone & Tissue.
DePuy Synthes Spine is the second largest spine company in the world with one of the most comprehensive portfolios of spinal care solutions that address key areas including thoracolumbar, cervical, aging spine, interbody fusion, and MIS surgery. The company's leading solutions include EXPEDIUM VERSE® Spinal System to treat spinal conditions ranging from scoliosis to degenerative disc disease; the CONCORDE® Systems & SYNCAGE® Evolution System to treat the Lumbar spine; the VIPER 2 and VIPER 3D™ System for MISS; SYNAPSE™ System and the ZERO-P® Family of Implants to treat the cervical spine and finally, a suite of biomaterial solutions like DBX.
Yungjin Pharm. Co., Ltd was established in 1952, has been playing a major role as a forerunner in the Korean pharmaceutical industry for half a century. With our inspiring mission statement, "To relieve the suffering of mankind from diseases with our innovative, effective and safe pharmaceutical products", we have shown our successful contribution not only within Korea, but also through global expansion. As a result, we have received a total of 25 awards including the President Award for Superior Product Development, the Prime Minister Award, Industry Award and many more. These accomplishments demonstrate our sustainability and commitment to the development of innovative products and business excellence in both overseas and domestic segments.
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a global, integrated healthcare services and products company, providing customized solutions for hospitals, health systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide.
The company provides clinically-proven medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency from hospital to home. Cardinal Health connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. Backed by nearly 100 years of experience, with approximately 50,000 employees in 46 countries, Cardinal Health ranks among the top 25 on the Fortune 500.
Cardinal Health is more than a business, more than a partner, more than hard workers. It’s wings. Its unrivaled scale and focused approach leads to better solutions. The company’s strength flows from four areas of expertise: logistics, product, business and patient solutions. Cardinal Health welcomes new challenges, anticipates trends, and as Wings, brings support, speed, and mile-high vision to all customers.
First decision
29 Days
Publication after acceptance
77 Days
Submission to publication
144 Days
Acceptance rate
14 %
*Last 12 months